Lawrence B. Leisure
Known title: DirectorCIK: 0001642824
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
PIII appoints new Chief Clinical Officer. P3 Health Partners announced the appointment of a new Chief Clinical Officer. The executive will oversee clinical operations and strategy for the company. This addition brings additional expertise as the firm pursues its growth plans. The stock is currently trading with a low RSI and near its recent support level.
Transaction History
| DRIO | ▲ Buy | Grant | 20,000 | $0 | 9/11/2025 | View on chart |
| PIII | ▲ Buy | Grant | 2,000 | $0 | 8/6/2025 | View on chart |
| PIII | ▲ Buy | Grant | 216,561 | $0 | 10/23/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
DarioHealth's Aon Analysis Confirms 2.5%-7.2% Cost Reduction
DarioHealth released an independent Aon analysis that backs its estimate of a 2.5%–7.2% reduction in in‑year healthcare costs. The study adds credibility to the company’s cost‑efficiency claims and may influence how analysts view its valuation. The stock is trading near its $7.38 support level, within the 52‑week range of $5.84–$17.74. The analysis could affect investor sentiment as the company continues to pursue its growth strategy.
DarioHealth's Aon Analysis Confirms 2.5%-7.2% Cost Reduction. DarioHealth released an independent Aon analysis that backs its estimate of a 2.5%–7.2% reduction in in‑year healthcare costs. The study adds credibility to the company’s cost‑efficiency claims and may influence how analysts view its valuation. The stock is trading near its $7.38 support level, within the 52‑week range of $5.84–$17.74. The analysis could affect investor sentiment as the company continues to pursue its growth strategy.